Science 37 Holdings, Inc. disclosed the latest enrollment figures resulting from its Metasite? and Patient Recruitment partnership with a leading biotech company whose asthma drug is currently undergoing a Phase 3 clinical trial. Leveraging its proprietary Metasite?

and Patient Recruitment solutions, Science 37 contributed 28% of all randomized study participants over a 15-month enrollment window. Science 37 averaged 44 patients enrolled per month, while each of the 55 brick-and-mortar sites supporting the trial enrolled an average of two participants per month. Science 37 delivered an enrollment velocity 22x greater than study sites in the trial and reduced the study?s overall time-to-target enrollment.

Science 37?s Patient Recruitment is available on a standalone basis to clinical research sponsors and CROs looking to enhance their patient enrollment efforts, or in combination with Science 37?s Virtual Site, the Metasite?, as part of an accelerated research offering.